Article
Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small…
Drug Design, Development and Therapy · 2014 · Ren T, Shan J, Qing Y, Qian C, Li Q, Lu G, Li M, Li C, Peng Y, Luo H, Zhang S, Zhang W, Wang D, Zhou SF
Key facts
| Title | Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway |
|---|---|
| First author | Ren T, Shan J, Qing Y, Qian C, Li Q, Lu G, Li M, Li C, Peng Y, Luo H, Zhang S, Zhang W, Wang D, Zhou SF |
| Journal | Drug Design, Development and Therapy |
| Published | Dec 12, 2014 |
| DOI | 10.2147/DDDT.S71432 |
| Devices mentioned | K792138, K973350, K990827 |
| Product codes mentioned | CEK, JLX, KQP |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1